News
More than half of biotech and pharma job seekers have been looking for their next opportunity for six months or longer, and more than a quarter have searched for over a year, according to a BioSpace LinkedIn poll. Job seekers share their frustrations.
FEATURED STORIES
PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing through trials in lung cancer. But the potential of these drugs may be highest in cancers where angiogenesis and immune escape are tightly intertwined.
From Eli Lilly’s David Ricks to Pfizer’s Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025.
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
FDA veteran Peter Marks will now shape the future of Eli Lilly’s vaccines work after the buys of Curevo, LimmaTech Biologics and Vaccine Company for up to $3.8 billion total.
THE LATEST
MaaT Pharma announced that the U.S. FDA has maintained the clinical hold on MaaT013, its candidate for patients with steroid-resistant acute graft-versus-host disease.
Versant Ventures launched Vector BioPharma, a company developing a “precision gene delivery platform that is devoid of viral genes.” Rani, REVA Medical and Summit Therapeutics also scored funds.
Gemini Therapeutics and Disc Medicine have announced plans to merge in an all-stock deal. The combined company will work to advance Disc’s pipeline of hematology programs.
Monkeypox is spreading, COVID-19 stubbornly persists and on Tuesday, news broke of a Langya henipavirus outbreak in China.
Endo International filed for bankruptcy Tuesday in the U.S. Bankruptcy Court in New York due to its debt load of over $8 billion and the thousands of opioid lawsuits.
The FDA will still allow continued distribution of sitagliptin containing NTTP with an acceptable intake limit of 37 ng per day and up to 246.7 ng per day.
In partnership with GentiBio, BMS aims to harness the capabilities of engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with IBD.
Attending a networking event isn’t enough – you have to make the most of it. To be successful, you need to be strategic about who you talk to, what you say, and how you follow up to get the best candidates.
As organizations implement diversity initiatives, they often need a leader to guide them in the right direction. Find out what DEI leadership is and how it can help your business in our guide.
When vetting the qualities of potential candidates at a career fair, listen to and take interest in the unique lived experiences of each job seeker you meet, as well as their skills and qualifications.